作者投稿
专家审稿
编辑办公
邮件订阅
RSS
-
摘要:
目的 评估我国生物样本库的运营规划现状。 方法 对国内63个主要生物样本库展开问卷调查。问卷内容包括生物样本库基本信息、运营规划、样本利用率、用户/客户群体、市场推广/广告、成本回收和业绩指标等6个类别, 对6个类别的调查数据进行描述性分析。 结果 63个生物样本库中, 96.8%(61/63)属于学术机构或公立医院; 19.0%(12/63)已有运营规划, 39.7%(25/63)正在筹备运营规划, 41.3%(26/63)尚无运营规划; 85.0%(34/40)实际利用率低于20%, 且97.5%(39/40)低于目标利用率; 88.6%(1084/1223)的样本仅用于样本库或所属机构内部使用, 不对外共享。 结论 本次调查结果初步反映, 我国生物样本库运营规划情况不容乐观, 样本实际利用率较低, 且普遍低于其目标利用率, 对外共享不足, 未来应进一步加强国内生物样本库的合作和共享。 Abstract:Objective This study aimed to gauge the current state of biobank business planning in China. Methods We conducted a survey among the directors or main participants of 63 biobanks in China. The questionnaire had six categories, including basic information about the biobanks, business planning, utilization, users/customers, marketing/advertising, and cost recovery/performance measures. In this report, we presented a descriptive analysis of the responses in the survey. Results In our survey, 96.8% (61/63)of the biobanks belonged to academic institutes or public hospitals; 19.0%(12/63) had business plans; 39.7%(25/63) had a business plan in progress; 41.3%(26/63) had no business plan. In 85.0%(34/40) of the biobanks, the actual utilization rate was less than 20%; and in 97.5%(39/40) of the biobanks, the actual utilization rate of their bio-specimen collections was generally lower than the targeted one. About 88.6%(1084/1223) samples were for internal use but not shared externally. Conclusions According to the results of this survey, the situation of biobank business planning in China is not so optimistic. The actual utilization rates of most biobanks were generally lower than their goals, and the main problem was lack of sharing. Cooperation and sharing of domestic biobanks should be further strengthened. -
Key words:
- biobank /
- business planning /
- sustainable development
-
表 2 63个生物样本库的样本利用率分布情况
实际利用率(%) 目标利用率(%) 总计 0~20 ＞20~40 ＞40~60 ＞60~80 ＞80~100 0~20 8 9 12 2 3 34 ＞20~40 2 1 2 5 ＞40~60 ＞60~80 1 1 ＞80~100 
下载: 导出CSV
表 3 56个生物样本库存储的样本总数分布情况
样本库类型 样本总数(份) 样本库(个) 百分比(%) 小型 0 2 3.6 1~5000 5 8.9 5001~25 000 11 19.6 25 001~100 000 16 28.6 100 001~250 000 8 14.3 中型 250 001~500 000 6 10.7 500 001~2 000 000 7 12.5 大型 2 000 001~5 000 000 1 1.8 超大型 ＞5 000 000 0 0 总计 56 100
下载: 导出CSV
表 4 16个生物样本库成本回收率分布情况
估计成本回收率(%) 目标成本回收率(%) 总计 0~20 ＞20~40 ＞40~60 ＞60~80 ＞80~100 0~20 1 7 3 1 12 ＞20~40 1 1 ＞40~60 1 1 2 ＞60~80 1 1 ＞80~100 总计 1 7 4 4 16
下载: 导出CSV
-
[1] 陆怡.转化医学与生物样本库现状[J].生命的化学, 2012, 32:287-293. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=smdhx201203018 [2] 赵晓航, 钱阳明.生物样本库-个体化医学的基础[J].转化医学杂志, 2014, 3:69-74. doi: 10.3978/j.issn.2223-4683.2014.s069 [3] 郜恒骏.中国生物样本库向标准化迈进[J].中国医药生物技术杂志, 2015, 10:481-483. http://www.cqvip.com/QK/88816X/20156/666843584.html [4] 董尔丹, 胡海, 俞文华, 等.生物样本库是生物医学研究的重要基础[J].中国科学:生命科学, 2015, 45:359-370. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgkx-cc201504004 [5] 郜恒骏, 杜祥, 樊嘉, 等.中国生物样本库理论与实践[M]北京:科学出版社, 2017:6. [6] Tamminen S.Bio-objectifying European bodies:standardisa-tion of biobanks in the Biobanking and Biomolecular Resources Research Infrastructure[J].Life Sci Soc Policy, 2015, 11:13. doi: 10.1186/s40504-015-0031-1 [7] Vaught J.Biobanking comes of age:The Transition to Biospecimen Science[J].Annu Rev Pharmacol Toxicol, 2016, 56:211-228. doi: 10.1146/annurev-pharmtox-010715-103246 [8] Birch K, Dove ES, Chiappetta M, et al.Biobanks in Oral Health:Promises and Implications of Post-Neoliberal Science and Innovation[J].OMICS, 2016, 20:36-41. doi: 10.1089/omi.2015.0123 [9] Macheiner T, Huppertz B, Bayer M.Challenges and Driving Forces for Business Plans in Biobanking[J].Biopreserv Biobank, 2017, 15:121-125. doi: 10.1089/bio.2017.0018 [10] Simeon-Dubach D, Goldring K, Henderson MK.Trends in Biobanking Business Planning:Initial Results of a Survey of Biobankers[J].Biopreserv Biobank, 2017, 5:72-74. http://www.ncbi.nlm.nih.gov/pubmed/27936871 [11] Ciaburri M, Napolitano M, Bravo E.Business Planning in Biobanking:How to Implement a Tool for Sustainability[J].Biopreserv Biobank, 2017, 15:46-56. doi: 10.1089/bio.2016.0045 [12] Yuille MM, Feller PI, Georghiou L, et al.Financial Sustainability of Biobanks:From Theory to Practice[J].Biopreserv Biobank, 2017, 15:85-92. doi: 10.1089/bio.2017.29019.mjy [13] Tarling TE, Lasser F, Carter C, et al.Business Planning for a Campus-Wide Biobank[J].Biopreserv Biobank, 2017, 15:37-45. doi: 10.1089/bio.2016.0077 [14] 郭渝成, 郜恒骏, 尹岭, 等.临床生物样本库[M].北京:科学出版社, 2014:1-7. [15] 王剑萍, 蔡美玉, 孙孟红, 等.上海市公立医院生物样本库的现状分析[J].中华医学科研管理杂志, 2016, 29:C2-C4. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhyxkyglzz201605022 -
点击查看大图
图(1) / 表(4)
计量
- 文章访问数: 383
- HTML全文浏览量: 44
- PDF下载量: 442
- 被引次数: 0
